Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 2Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Fulvestrant 3Alpelisib 3parsaclisib 2Paclitaxel 2Irinotecan 2Cetuximab 2Carboplatin 2tanezumab 1talazoparib 1sotorasib 1serabelisib 1sapanisertib 1ruxolitinib 1olaparib 1niraparib 1liposomal doxorubicin 1inavolisib 1dapagliflozin 1ceralasertib 1binimetinib 1berzosertib 1avelumab 1Vemurafenib 1Topotecan 1Taxes 1SF 1126 1Oxaliplatin 1Lomustine 1Leuprolide 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Sensory and Autonomic Neuropathies × berzosertib × Clear all
NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

EMD Serono

Phase 2 Completed
76 enrolled 42 charts
Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡